Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review

Fig. 1

Cognitive and pathological heterogeneity in APOE4+ vs. APOE4− AD patients. A representation of the heterogeneity reported in APOE4+ vs. APOE4− AD patients. APOE4+ AD patients possess relatively more tau accumulation and brain atrophy in their medial temporal lobe, resulting in greater memory impairment, compared to APOE4− AD patients. On the other hand, APOE4− AD patients possess relatively more tau accumulation and brain atrophy in their fronto-parietal lobes, resulting in greater impairment in executive function, visuospatial abilities, and language, compared to APOE4+ AD patients. The level of tau accumulation (brown) represents the levels observed in AD brains during Braak stages V–VI

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193